Triangletrastuzumab-emtansine (NCT04893109)
trastuzumab-emtansine trial for Breast Cancer (NCT04893109). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults after surgery for stage I HER2-positive invasive breast cancer, with negative nodes or nodal micrometastases. HER2 status requires central confirmation.
The idea: T-DM1 attaches chemotherapy to a HER2-targeting antibody. Patients are randomized to six infusions every three weeks followed by trastuzumab injections, or twelve weeks of paclitaxel with trastuzumab continuing afterward. Total treatment lasts about one year. Researchers compare side effects and track disease-free survival. Radiation is required after breast-conserving surgery.
This phase 2 study plans 500 patients. Sara Tolaney leads at Dana-Farber; 46 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.